Return to search results
Botulinum toxin type a
DAXXIFY is a prescription injectable form of botulinum toxin type A, manufactured by Revance Therapeutics, Inc., used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows in adults. It works by blocking nerve signals to muscles, reducing wrinkles. Administered via intramuscular or subcutaneous injection, it's available as a lyophilized powder for solution in vials of 100 units per 1.2 mL. Approved in September 2022 under BLA761127. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | DAXXIFY is a prescription injectable form of botulinum toxin type A, manufactured by Revance Therapeutics, Inc., used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows in adults. It works by blocking nerve signals to muscles, reducing wrinkles. Administered via intramuscular or subcutaneous injection, it's available as a lyophilized powder for solution in vials of 100 units per 1.2 mL. Approved in September 2022 under BLA761127. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Botulinum toxin type a",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Botulinum toxin type a — ANDA 761127 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761127"
}
]
|
| identifier | ANDA761127 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-manufacturers",
"health-care",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Botulinum toxin type a |
